GIL Earnings

GIL reported its earnings on 2026-02-26, showcasing a revenue of against an estimate of 885.30M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.94 by 0%. The stock experienced a -3.07% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following GIL's earnings announcement on 2026-02-26, the stock price moved by -3.07% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, GIL's stock price tends to shift by an average of -1.81% in the 10 days leading up to earnings and 2.26% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate GIL's annual revenue to reach 1.50B, while the EPS is projected at 0.61. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between GIL's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, GIL's stock price typically moves by -1.81% in the 10 days before its earnings and 2.26% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.61 and revenue of 1.50B.

The earnings call summary indicates mixed results. Basic financial performance shows positive cash flow and asset sales progress, but EBITDA decline in the tissue segment is concerning. Product development is promising with innovation plans, but market strategy is unclear due to potential tariff impacts. The shareholder return plan lacks detail on capital allocation priorities. Q&A insights reveal confidence in price hikes and asset sales without EBITDA erosion, but management's unclear responses on tariffs and asset mix raise uncertainties. Overall, the sentiment is neutral, balancing positive and negative factors.